CUR - Neuralstem, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.91
+0.06 (+3.24%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.85
Open1.85
Bid1.86 x 800
Ask1.91 x 200
Day's Range1.82 - 1.91
52 Week Range0.88 - 6.60
Volume110,275
Avg. Volume1,560,345
Market Cap28.929M
Beta0.77
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube24 days ago

    ETFs with exposure to Neuralstem, Inc. : December 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Neuralstem, Inc. (CUR): Updated Phase II Trial Success in Major Depressive Disorder Takes the Street by Storm
    SmarterAnalystlast month

    Neuralstem, Inc. (CUR): Updated Phase II Trial Success in Major Depressive Disorder Takes the Street by Storm

    Neuralstem (NASDAQ:CUR) stock is on fire after revealing a huge clinical win that has sent bulls storming the market today to buy into piece of the biotech action. Shares are rocketing 100% on back of the drug maker's successful updated Phase 2 clinical data in major depressive disorder, where the company's NSI-189 asset impressed at the 56th American College of Neuropsychopharmacology (ACNP) Annual meeting.

  • Does Neuralstem Inc’s (CUR) Past Performance Indicate A Stronger Future?
    Simply Wall St.2 months ago

    Does Neuralstem Inc’s (CUR) Past Performance Indicate A Stronger Future?

    Examining Neuralstem Inc’s (NASDAQ:CUR) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met or exceedRead More...

  • Associated Press2 months ago

    Neuralstem reports 3Q loss

    On a per-share basis, the Germantown, Maryland-based company said it had a loss of 18 cents. The biopharmaceutical company posted revenue of $2,500 in the period. Its adjusted revenue was $3,000. The company's ...

  • Capital Cube2 months ago

    ETFs with exposure to Neuralstem, Inc. : November 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Neuralstem, Inc. :CUR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
    Capital Cube2 months ago

    Neuralstem, Inc. :CUR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017

    Categories: Yahoo FinanceGet free summary analysis Neuralstem, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Neuralstem, Inc. – Cytokinetics, Incorporated, Geron Corporation, Acorda Therapeutics, Inc., Aceto Corporation, Intra-Cellular Therapies, Inc., Supernus Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc. (CYTK-US, GERN-US, ACOR-US, ACET-US, ITCI-US, SUPN-US and ... Read more (Read more...)

  • One Thing To Consider Before Buying Neuralstem Inc (CUR)
    Simply Wall St.3 months ago

    One Thing To Consider Before Buying Neuralstem Inc (CUR)

    For Neuralstem Inc’s (NASDAQ:CUR) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Every stock in theRead More...

  • Capital Cube4 months ago

    ETFs with exposure to Neuralstem, Inc. : September 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube4 months ago

    ETFs with exposure to Neuralstem, Inc. : September 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • TheStreet.com4 months ago

    Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers

    Standard treatments can cause motor side effects and/or weight gain, cardiovascular complications, dyslipidemia, and hyperglycemia.

  • Capital Cube5 months ago

    ETFs with exposure to Neuralstem, Inc. : August 31, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Neuralstem, Inc. :CUR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
    Capital Cube5 months ago

    Neuralstem, Inc. :CUR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Neuralstem, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Neuralstem, Inc. – Titan Pharmaceuticals, Inc., Cytokinetics, Incorporated, Acorda Therapeutics, Inc., Geron Corporation, Neurocrine Biosciences, Inc., Albany Molecular Research, Inc., BioTime, Inc., Charles River Laboratories International, Inc. and Repligen ... Read more (Read more...)

  • Associated Press5 months ago

    Neuralstem reports 2Q loss

    The Germantown, Maryland-based company said it had a loss of 39 cents per share. The biopharmaceutical company posted revenue of $2,500 in the period. Its adjusted revenue was $3,000. The company's shares ...

  • Capital Cube7 months ago

    ETFs with exposure to Neuralstem, Inc. : July 4, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube8 months ago

    ETFs with exposure to Neuralstem, Inc. : June 2, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Neuralstem, Inc. :CUR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
    Capital Cube8 months ago

    Neuralstem, Inc. :CUR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017

    Categories: Yahoo FinanceGet free summary analysis Neuralstem, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Neuralstem, Inc. – Titan Pharmaceuticals, Inc., Cytokinetics, Incorporated, Acorda Therapeutics, Inc., Geron Corporation, Neurocrine Biosciences, Inc., Albany Molecular Research, Inc., Aceto Corporation, BioTime, Inc., Charles River Laboratories International, Inc. ... Read more (Read more...)

  • Capital Cube8 months ago

    ETFs with exposure to Neuralstem, Inc. : May 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Associated Press8 months ago

    Neuralstem reports 1Q loss

    The Germantown, Maryland-based company said it had a loss of 68 cents per share. Losses, adjusted for non-recurring costs, were 43 cents per share. The biopharmaceutical company posted revenue of $2,500 ...

  • Capital Cube9 months ago

    ETFs with exposure to Neuralstem, Inc. : April 19, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube9 months ago

    ETFs with exposure to Neuralstem, Inc. : April 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Neuralstem, Inc. :CUR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017
    Capital Cube10 months ago

    Neuralstem, Inc. :CUR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017

    Categories: Yahoo Finance Get free summary analysis Neuralstem, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Neuralstem, Inc. – Titan Pharmaceuticals, Inc., Cytokinetics, Incorporated, Acorda Therapeutics, Inc., Geron Corporation, Albany Molecular Research, Inc., BioTime, Inc., Neurocrine Biosciences, Inc., Aceto Corporation, Charles River Laboratories International, Inc. ... Read more (Read more...)

  • Neuralstem, Inc. (CUR) Is Up. Here’s Why And What It Means
    Insider Monkey11 months ago

    Neuralstem, Inc. (CUR) Is Up. Here’s Why And What It Means

    Neuralstem, Inc. (NASDAQ:CUR) is a big runner at the end of this week, as the company puts out an update on its lead major depressive disorder (MDD) trial. The trial is investigating the safety and efficacy of an asset called NSI-189, and it’s a phase II study. On the update, Neuralstem, Inc. (NASDAQ:CUR) gained gained […]